Today, 12,819 Shares of Editas Medicine Inc. (EDIT) Stock are sold by Polaris Venture Management Co.

Today, 12,819 Shares of Editas Medicine Inc. (EDIT) Stock are sold by Polaris Venture Management Co.
Editas Medicine Inc. (NASDAQ:EDIT) major shareholder Polaris Venture Management Co. sold 12,819 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $15.77, for a total value of $202,155.63. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Polaris Venture Management Co. also recently made the following trade(s): On Thursday, September 8th, Polaris Venture Management Co. sold 500,000 shares of Editas Medicine stock. The stock was sold at an average price of $16.80, for a total value of $8,400,000.00.

Editas Medicine Inc. (NASDAQ:EDIT) opened at 15.68 on Friday. The company’s 50-day moving average price is $14.53 and its 200-day moving average price is $21.81. Editas Medicine Inc. has a one year low of $12.43 and a one year high of $43.99. The stock’s market capitalization is $558.74 million.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Monday, November 7th. The company reported ($0.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.64) by $0.05. Editas Medicine had a negative return on equity of 59.22% and a negative net margin of 1,184.46%. The company earned $1 million during the quarter, compared to analysts’ expectations of $1 million. Editas Medicine’s revenue for the quarter was up 49.3% on a year-over-year basis. Equities research analysts predict that Editas Medicine Inc. will post ($2.49) EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors bought a new position in Editas Medicine during the second quarter worth $115,000. BlackRock Group LTD bought a new position in Editas Medicine during the third quarter worth $117,000. BlackRock Advisors LLC boosted its position in Editas Medicine by 11.2% in the third quarter. BlackRock Advisors LLC now owns 9,817 shares of the company’s stock worth $132,000 after buying an additional 990 shares during the period. PARK CIRCLE Co bought a new position in Editas Medicine during the third quarter worth $135,000. Finally, Metropolitan Life Insurance Co. NY bought a new position in Editas Medicine during the second quarter worth $181,000. 59.88% of the stock is owned by institutional investors.

EDIT has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, September 20th. Jefferies Group reiterated a “buy” rating on shares of Editas Medicine in a report on Monday, August 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $30.75.

About Editas Medicine

Related posts

Leave a Comment